Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

Launched by HANNAH SCHAEFER · Dec 2, 2024

Keywords

ClinConnect Summary

The KiRi-Trial is a study designed to understand how a specific treatment for prostate cancer, called 177Lutetium-PSMA Radioligand Therapy, affects kidney function over time. Researchers want to find out how much kidney function decreases in men with metastatic castration-resistant prostate cancer (mCRPC) after receiving this therapy, looking closely at their kidney health at 12 and 24 months. To do this, they will measure kidney function using common tests and track other factors that could indicate early signs of kidney problems.

This study is open to men aged 65 to 74 who are starting their first cycle of 177Lu-PSMA-RLT at a particular hospital. Participants will have their kidney health monitored regularly for up to five years, which means they can expect several check-ups throughout the study. The researchers also want to see how different health factors and personal experiences affect kidney health, helping to identify patients who may be at higher risk for kidney issues. If you're eligible and decide to join, you'll be contributing valuable information that could improve care for future patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with mCRPC starting 177Lu-PSMA RLT at the Klinikum rechts der Isar at the time of therapy initiation (1st cycle).
• Exclusion Criteria:
• • Missing or incomplete informed consent.
• • age below 18 years